Lidds AB   Report issue

For profit Phase 1 Phase 2
Founded: Uppsala Sweden (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2009
NCT00913263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Lidds AB

Active Ingredients

Drugs in Phase 2 Trials (1)

2-hydroxyflutamide (3 trials)

Drugs in Phase 1 Trials (1)

docetaxel (taxotere) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2